How Much Less Do You Eat on a GLP-1? What the Buffet-Lunch Studies Measured, and What It Means for Microdosing

Ask people on a GLP-1 what changed and most describe a feeling. Half a sandwich is enough. The second helping stops looking interesting. Feelings are hard to compare, though, so researchers use a blunter tool: a standardized breakfast, then a lunch tray loaded with far more food than anyone needs, and a scale to weigh what comes back.

This article walks through those buffet-lunch studies for semaglutide, oral semaglutide, liraglutide and tirzepatide. It covers how big the GLP-1 calorie intake drop is, whether it lasts, whether a higher dose buys more of it, and what that implies for people using lower doses. One caution applies to every number below. None of these trials tested a microdose. They describe what standard doses do, which is useful context, not a promise about smaller ones.

How much less do you eat on a GLP-1, according to the trials?

At standard doses, people on a GLP-1 medicine eat somewhere between about a sixth and two-fifths less at a free-choice meal than people on placebo. The spread depends on the drug, the dose, how long people had been taking it and whether researchers counted one lunch or a whole day of meals.

Blundell and colleagues ran one of the first of these trials with weekly semaglutide, published in Diabetes, Obesity and Metabolism (2017). Thirty adults with obesity took semaglutide escalated to 1.0 mg, then placebo, for 12 weeks each. After a standard breakfast, they ate 1255 kJ less at lunch and less again at dinner and snacks, a 24% cut in total energy intake across the day. Weight fell by 5.0 kg, mostly fat.

Oral semaglutide shows a similar pattern. Gibbons and colleagues (Diabetes, Obesity and Metabolism, 2021) gave 15 adults with type 2 diabetes daily tablets stepped from 3 to 7 to 14 mg over 12 weeks. In 13 evaluable people, total daily intake was 38.9% lower than on placebo. Gabe and colleagues (Diabetes, Obesity and Metabolism, 2024) tested a much higher 50 mg oral dose in 61 adults with obesity and found lunch intake down 39.2 percentage points versus placebo at week 20.

What does a GLP-1 do to a single meal?

On semaglutide 2.4 mg, a single free-choice lunch shrank by about a third. Friedrichsen and colleagues, in Diabetes, Obesity and Metabolism (2021), randomized 72 adults with obesity to weekly semaglutide escalated to 2.4 mg or placebo for 20 weeks, then measured what they ate when offered as much lunch as they wanted.

The semaglutide group ate 1736 kJ against 2676 kJ on placebo, a difference of 940 kJ or 35%. Participants also reported less hunger, more fullness, better control of eating and fewer and weaker cravings. Those subjective changes are the part people notice. The tray on the scale is the part that moves body weight.

Is it the slow stomach, or the brain?

Slower stomach emptying does not seem to be the main reason people eat less after several months on a GLP-1. Friedrichsen's semaglutide 2.4 mg trial found no evidence of delayed gastric emptying at week 20, measured indirectly by paracetamol absorption. An early 8% rise in the absorption curve was no longer significant once body weight was accounted for. Gabe's 20-week oral semaglutide study likewise found no significant difference in gastric emptying, even with lunch intake 39.2 percentage points lower.

Brain-level appetite effects fit the data better. Martin and colleagues, in Nature Medicine (2025), randomized 114 adults without diabetes and a BMI of 27 to 50 to tirzepatide, placebo or liraglutide for 6 weeks. By week 3, tirzepatide cut lunch intake by 524.6 kcal versus placebo. It also lowered cravings, the tendency to overeat and reactivity to food in the environment, but it did not change deliberate dietary restraint. In other words, people were not trying harder. The pull of food was weaker.

That matches what many people describe as quieter food noise, which our article on GLP-1 and food noise covers in more depth. Blundell's semaglutide trial also found a lower relative preference for high-fat foods, so the change is partly in what people choose, not only how much.

Does the effect wear off after a few months?

The reduction in calories held for more than a year in the longest study, even after people stopped feeling much different. Tronieri and colleagues, in The American Journal of Clinical Nutrition (2026), randomized 120 adults with overweight or obesity 3:2 to semaglutide 2.4 mg or placebo for 60 weeks and tested lunch intake at weeks 20, 40 and 60.

The semaglutide group ate 291.9 kcal less than placebo at week 20, 240.2 kcal less at week 40 and 269.5 kcal less at week 60. Their appetite ratings told a different story. At week 20 they reported more suppression after breakfast and less hunger and food preoccupation, but by weeks 40 and 60 the appetite scores no longer differed from placebo.

That gap matters for anyone who thinks a GLP-1 has stopped working because the early fullness faded. In this trial, the felt effect faded while the measured effect on intake stayed. The authors concluded that eating less is a central mechanism for both losing weight and keeping it off on semaglutide. For more on why weight still stalls despite this, see our piece on the GLP-1 weight-loss plateau.

Does a higher dose mean eating even less?

In the only study here that compared two doses of the same drug, a higher dose did not reduce intake any further. Van Can and colleagues, in the International Journal of Obesity (2014), gave 49 non-diabetic adults with obesity liraglutide 1.8 mg, liraglutide 3.0 mg or placebo in a crossover design and tested them after 5 weeks on each.

Both doses raised fullness, cut hunger and reduced lunch intake by about 16%. Where the doses differed was the stomach: 1-hour gastric emptying was 23% slower than placebo on 3.0 mg and a nonsignificant 13% slower on 1.8 mg. The extra dose bought more early stomach slowing, which tends to show up as nausea and fullness, without a matching extra drop in what people ate at that point.

This is the most relevant finding for microdosing, and it has to be read carefully. It is one 5-week study of liraglutide, and 1.8 mg is still a full therapeutic dose, not a microdose. It suggests the intake curve may flatten before the side-effect curve does. It does not show that a dose far below 1.8 mg keeps the same benefit. Our guide to low-dose semaglutide for weight loss looks at what the dose-ranging trials show for weight.

Does tirzepatide cut calories more than semaglutide?

At the lunch table, tirzepatide and semaglutide look similar in the one direct comparison. Heise and colleagues, in Diabetes Care (2023), studied people with type 2 diabetes on tirzepatide 15 mg (45 people), semaglutide 1 mg (44 people) or placebo (28 people) for 28 weeks. Both drugs reduced appetite versus placebo, and their effects on appetite scores and test-lunch intake did not differ.

Tirzepatide still produced more weight loss and more fat loss. The authors wrote that differences in lunch intake were not enough to explain the gap and called for work on 24-hour intake, fuel use and energy expenditure. A single lunch is a narrow window, so the honest reading is that tirzepatide's extra weight loss is not yet fully explained.

Quan and colleagues' 2026 meta-analysis in Diabetes & Metabolic Syndrome reviewed 16 studies and pooled the 3 placebo-controlled trials that used a standardized lunch test. The pooled drop was 1132 kJ, about 271 kcal, with no heterogeneity between trials. Adding the short tirzepatide trial made the effect larger but much less consistent, and the semaglutide-versus-tirzepatide difference was not significant.

Does eating less explain the weight loss, or do GLP-1s raise metabolism?

Eating less explains most of it, according to these trials. In Blundell's semaglutide study, resting metabolic rate adjusted for lean mass did not differ from placebo. The liraglutide study concluded that weight loss was driven by reduced appetite and intake rather than higher energy expenditure. Nothing here suggests GLP-1 medicines work by burning more calories.

The two 20-week semaglutide trials line up neatly. The injection group lost 9.9% of body weight against 0.4% on placebo, and the oral 50 mg group lost 9.8% against 1.5%. In both, the drop in intake came first and the weight followed. Metabolic adaptation, the slowing of energy use as weight falls, is a separate question covered in our article on metabolic adaptation on a GLP-1 microdose.

What does this mean for someone on a GLP-1 microdose?

For a microdose, these studies set expectations rather than predict results. The calorie drops above came from full therapeutic doses, and the lowest maintenance doses measured were liraglutide 1.8 mg daily and semaglutide 1.0 mg weekly. A smaller dose should be expected to do less, by an amount nobody has measured. A few practical points still follow from the evidence that exists:

• Judge a lower dose by what you eat, not only by how full you feel. In the 60-week trial, appetite ratings returned to placebo levels while intake stayed lower.
• Do not assume more is always better. In the liraglutide comparison, the higher dose slowed the stomach more without cutting lunch intake further.
• Watch protein when intake falls. The 2026 meta-analysis noted that real-world intake is underreported and recommended counseling that emphasizes adequate protein. Our protein guide for GLP-1 microdosing has the details.
• A short food log helps. Buffet-lunch numbers describe groups in a lab, and a week or two of your own records shows what your intake actually looks like.

Frequently asked questions

Clinical references

1. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017. doi:10.1111/dom.12932
2. Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021. doi:10.1111/dom.14280
3. Gibbons C, Blundell J, Tetens Hoff S, et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism. 2021. doi:10.1111/dom.14255
4. Gabe MBN, Breitschaft A, Knop FK, et al. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15802
5. van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International Journal of Obesity. 2014. doi:10.1038/ijo.2013.162
6. Heise T, DeVries JH, Urva S, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023. doi:10.2337/dc22-1710
7. Martin CK, Carmichael OT, Carnell S, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature Medicine. 2025. doi:10.1038/s41591-025-03774-9
8. Tronieri JS, Allison KC, DeRouen K, et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. The American Journal of Clinical Nutrition. 2026. doi:10.1016/j.ajcnut.2026.101403
9. Quan AT, Nguyen HL, Nguyen TMT, et al. Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome. 2026. doi:10.1016/j.dsx.2026.103466